Pangea Biomed

Executive Summary

Pangea Biomed is an Israeli precision‑oncology company that harnesses its proprietary ENLIGHT platform to transform cancer treatment selection. By integrating multi‑omics data, bioinformatics, and machine learning, ENLIGHT constructs gene‑social networks and functional interaction maps that reveal therapeutic vulnerabilities beyond traditional genomic mutations. This approach enables personalized prediction of tumor response, offering the potential to nominate optimal treatments for individual patients. Founded in 2018 and based in Haifa, the company has grown to 50-200 employees and operates as a platform stage private entity, positioning itself at the forefront of AI‑driven oncology. The company has demonstrated proof‑of‑concept through collaborations and internal studies, though specific financial details remain undisclosed. Pangea Biomed’s technology addresses a critical gap in oncology—moving beyond single‑gene biomarkers to a holistic view of tumor biology. If validated in large‑scale trials, ENLIGHT could significantly improve patient outcomes and reduce trial‑and‑error prescribing. Near‑term focus includes expanding pharmaceutical partnerships and publishing clinical validation data, which could accelerate adoption and capture value in the multi‑billion‑dollar precision oncology market.

Upcoming Catalysts (preview)

• Q3 2026Validation study publication in a high‑impact journal70% success
• Q4 2026Major pharmaceutical partnership for drug response prediction60% success
• Q2 2027Platform expansion to additional cancer indications50% success